Seek and destroy: The use of natural compounds for targeting the molecular roots of cancer

Current Drug Targets

Volumn 13, Issue 8, 2012, Pages 1072-1082

  Souza, Ana C S ^a   de Fátima, Ângelo ^b   da Silveira, Rafael B ^c   Justo, Giselle Z ^d  

^a UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Anticancer agents; Apoptosis; Cancer; Cell cycle; Cell death; Natural products; Signal transduction

Indexed keywords

APIGENIN; BETULIC ACID; ETOPOSIDE; GONIOTHALAMIN; NATURAL PRODUCT; PACLITAXEL; ROMIDEPSIN; TACROLIMUS; TENIPOSIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DRUG TARGETING; HUMAN; MITOSIS; NONHUMAN;

APOPTOSIS; BIOLOGICAL AGENTS; CELL CYCLE; DRUG DESIGN; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84863558277     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802008991     Document Type: Article

References (147)

1. Twombly R. Cancer surpasses heart disease as leading cause of death of all but the very elderly. J Natl Cancer Inst 2005; 97: 330-1.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Levitzki A, Klein S. Signal transduction therapy of cancer. Mol Aspects Med 2010; 31: 287-329.
4. Bailly C. Ready for a comeback of natural products in oncology. Biochem Pharmacol 2009; 77: 1447-57.
5. Strohl WR. The role of natural products in a modern drug discovery program. Drug Discov Today 2000; 5: 39-41.
6. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
7. Deorukhkar A, Krishnan S, Sethi G, Aggarwal BB. Back to basics: how natural products can provide the basis for new therapeutics. Expert Opin Investig Drugs 2007; 16:1753-73.
8. Newman DJ, Cragg GM. Microbial antitumor drugs: natural products of microbial origin as anticancer agents. Curr Opin Invest Drugs 2009; 10: 1280-96.
9. Harvey A. The role of natural products in drug discovery and development in the new millennium. IDrugs 2010; 13: 70-2.
10. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-77.
11. Vuorelaa P, Leinonenb M, Saikkuc P, et al. Natural products in the process of finding new drug candidates. Curr Med Chem 2004; 11: 1375-89.
12. Zhang L, An R, Wang J, et al. Exploring novel bioactive compounds from marine microbes. Curr Opin Microbiol 2005; 8: 276-81.
13. Zengler K, Toledo G, Rappé M, et al. Cultivating the uncultured. Proc Natl Acad Sci USA 2002; 99: 15681-6.
14. Knight V, Sanglier JJ, DiTullio D, et al. Diversifying microbial natural products for drug discovery. Appl Microbiol Biotechnol 2003; 62: 446-58.
15. Galeano E, Rojas JJ, Martínez A. Pharmacological developments obtained from marine natural products and current pipeline perspective. Nat Prod Commun 2011; 6: 287-300.
16. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 2009; 325: 161-5.
17. Koehn FE. High impact technologies for natural products screening. Prog Drug Res 2008; 65: 177-210.
18. Pettit RK. Mixed fermentation for natural product drug discovery. Appl Microbiol Biotechnol 2009; 83: 19-25.
19. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng 1969; 11: 1101-10.
20. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Sem Oncol 1992; 19: 670-86.
21. Dickens ML, Strohl WR. Isolation and characterization of a gene from Streptomyces sp. strain C5 that confers the ability to convert daunomycin to doxorubicin on Streptomyces lividans TK24. J Bacteriol 1996; 178: 3389-95.
22. Walczak RJ, Dickens ML, Priestley ND, Strohl WR. Purification, properties, and characterization of recombinant Streptomyces sp. strain C5 DoxA, a cytochrome P-450 catalyzing multiple steps in doxorubicin biosynthesis. J Bacteriol 1999; 181: 298-304.
23. Hutchinson CR, Colombo AL. Genetic engineering of doxorubicin production in Streptomyces peucetius: a review. J Ind Microbiol Biotechnol 1999; 23: 647-52.
24. Singh BK, Macdonald CA. Drug discovery from uncultivable microorganisms. Drug Discov Today 2010; 15: 792-9.
25. Breinbauer R, Vetter IR, Waldmann H. From protein domains to drug candidates-natural products as guiding principles in the design and synthesis of compound libraries. Angew Chem Int Ed Engl 2002; 41: 2879-90.
26. Stahl P, Kissau L, Mazitschek R, Giannis A, Waldmann H. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors. Angew Chem Int Ed Engl 2002; 41: 1174-8.
27. Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J Med Chem 2003; 46: 2917-31.
28. Bai R, Cichacz ZA, Herald CL, Pettit GR, Hamel E. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol 1993; 44: 757-66.
29. Sackett DL. Podophyllotoxin, steganacin and combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol Ther 1993; 59: 163-228.
30. Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52: 613-22.
31. Loganzo F, Discafani CM, Annable T, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003; 63: 1838-45.
32. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 2004; 52: 1-26.
33. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009; 22(Pt 15): 2579-85.
34. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
35. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001; 1: 370-7.
36. Bai R, Paull K, Herald C, Malspeis L, Pettit G, Hamel E. Halichondrin B and homohalichondrin B marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 1991; 266: 15882-9.
37. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-7.
38. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816-25.
39. Neergheen VS, Bahorun T, Taylor EW, Jen LS, Aruoma OI. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 2010; 278: 229-41.
40. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005; 100: 72-9.
41. Shi Q, Chen K, Li L, et al. Antitumor agents, 154. Cytotoxic and antimitotic flavonols from Polanisia dodecandra. J Nat Prod 1995; 58: 475-482. Erratum in: J Nat Prod 1995; 58: 1470.
42. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010; 596: 47-76.
43. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000; 1470: M79-M91.
44. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-33.
45. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on αβ-tubulin by electron crystallography. Science 2004; 305: 866-9.
46. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009; 8: 2086-95.
47. Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev advance online publication, 3 Mar 2011, doi:10.1002/med.20239.
48. Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulintargeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007; 18(Suppl 5): v9-v15.
49. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res 2008; 14: 1618-24.
50. Altmann KH, Gaugaz FZ, Schiess R. Diversity through semisynthesis: the chemistry and biological activity of semisynthetic epothilone derivatives. Mol Divers 2011; 15: 383-99.
51. Pryor DE, O'Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry 2002; 41: 9109-15.
52. Khrapunovich-Baine M, Menon V, Yang CP, et al. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation. J Biol Chem 2011; 286: 11765-78.
53. Bai R, Friedman SJ, Pettit GR, Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol 1992; 43: 2637-45.
54. Bai R, Edler MC, Bonate PL, et al. Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol 2009; 75: 218-26.
55. Ray A, Okouneva T, Manna T, et al. Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res 2007; 67: 3767-76.
56. Matson DR, Stukenberg PT. Spindle poisons and cell fate: a tale of two pathways. Mol Interv 2011; 11: 141-150.
57. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 2002; 64: 1375-86.
58. Ravelo AG, Estévez-Braun A, Chávez-Orellana H, Pérez-Sacau E, Mesa-Siverio D. Recent studies on natural products as anticancer agents. Curr Top Med Chem 2004; 4: 241-65.
59. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett 2008; 269: 315-25.
60. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-84.
61. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009; 36 (Suppl 3): S3-S17.
62. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007; 13: 433-42.
63. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
64. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996; 273: 239-42.
65. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
66. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1: 89-103.
67. McCubrey JA, Steelman LS, Kempf CR, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011; 226(11): 2762-81.
68. García-Echeverría C. Blocking the mTOR pathway: a drug discovery perspective. Biochem Soc Trans 2011; 39: 451-5.
69. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121: 1231-41.
70. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005; 106: 4261-8.
71. Nishioka C, Ikezoe T, Yang J, Gery S, Koeffler HP, Yokoyama A. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 2009; 125: 1710-20.
72. Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009; 16: 3-11.
73. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19(1): 107-20.
74. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124: 511-5.
75. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
76. Fulda S. Modulation of apoptosis by natural products for cancer therapy. Planta Med 2010; 76: 1075-9.
77. Ma X, Wang Z. Anticancer drug discovery in the future: an evolutionary perspective. Drug Discov Today 2009; 14: 1136-42.
78. Tan ML, Ooi JP, Ismail N, Moad AI, Muhammad TS. Programmed cell death pathways and current antitumor targets. Pharm Res 2009; 26: 1547-60.
79. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163.
80. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-60.
81. Cory S, Adams JM. The Bcl2 family: regulators of the cellular lifeor-death switch. Nat Rev Cancer 2002; 2: 647-56.
82. Ferreira CV, Justo GZ, Souza AC, et al. Natural compounds as a source of protein tyrosine phosphatase inhibitors: application to the rational design of small-molecule derivatives. Biochimie 2006; 88: 1859-73.
83. de Souza AC, Kodach L, Gadelha FR, et al. A promising action of riboflavin as a mediator of leukaemia cell death. Apoptosis 2006; 11: 1761-71.
84. Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci 2008; 9: 1096-107.
85. Fulda S, Debatin KM. Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review. Cancer Detect Prev 2006; 30: 217-23.
86. Durán M, Ponezi AN, Faljoni-Alário A, Teixeira MFS, Justo GZ, Durán N. Potential applications of violacein: a microbial pigment. Med Chem Res advance online publication, 10 May 2011, doi:10.1007/s00044-011-9654-9.
87. de Souza Queiroz KC, Zambuzzi WF, Santos de Souza AC, da Silva RA, Machado D, Justo GZ. A possible anti-proliferative and anti-metastatic effect of irradiated riboflavin in solid tumours. Cancer Lett 2007; 258: 126-34.
88. Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med Res Rev 2010; 30: 818-60.
89. Ruela-de-Sousa RR, Fuhler GM, Blom N, Ferreira CV, Aoyama H, Peppelenbosch MP. Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy. Cell Death Dis 2010; 1: e19.
90. Camargo CA, da Silva ME, da Silva RA, Justo GZ, Gomes-Marcondes MC, Aoyama H. Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in Walker 256 tumor-bearing rats. Biochem Biophys Res Commun 2011; 406: 638-42.
91. Durán N, Justo GZ, Ferreira CV, Melo PS, Cordi L, Martins D. Violacein: properties and biological activities. Biotechnol Appl Biochem 2007; 48 (Pt 3): 127-33.
92. Melo PS, Maria SS, Vidal BC, Haun M, Durán N. Violacein cytotoxicity and induction of apoptosis in V79 cells. In vitro Cell Dev Biol Anim 2000; 36: 539-43.
93. Melo PS, Justo GZ, de Azevedo MB, Durán N, Haun M. Violacein and its β-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology 2003; 186: 217-25.
94. Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Durán N, Peppelenbosch MP. Molecular mechanism of violacein-mediated human leukemia cell death. Blood 2004; 104: 1459-64.
95. Bromberg N, Justo GZ, Haun M, Durán N, Ferreira CV. Violacein cytotoxicity on human blood lymphocytes and effect on phosphatases. J Enzyme Inhib Med Chem 2005; 20: 449-54.
96. Bromberg N, Dreyfuss JL, Regatieri CV, et al. Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor. Chem Biol Interact 2010; 186: 43-52.
97. Kodach LL, Bos CL, Durán N, Peppelenbosch MP, Ferreira CV, Hardwick JC. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis 2006; 27: 508-16.
98. de Carvalho DD, Costa FT, Durán N, Haun M. Cytotoxic activity of violacein in human colon cancer cells. Toxicol In vitro 2006; 20: 1514-21.
99. Vandermolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) advance online publication, 18 May 2011; doi:10.1038/ja.2011.35.
100. Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo) 1994; 43: 315-23.
101. Mizutani H, Hiraku Y, Tada-Oikawa S, et al. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide. Cancer Sci 2010; 101: 2214-9.
102. Inoue S, Harper N, Walewska R, Dyer MJ, Cohen GM. Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 2009; 8: 3088-97.
103. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-67.
104. Odenike OM, Alkan S, Sher D, et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008; 14: 7095-101.
105. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009; 218: 13-21.
106. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 2010; 15: 668-78.
107. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010; 10: 842-57.
108. Vilella D, Sánchez M, Platas G, et al. Inhibitors of farnesylation of Ras from a microbial natural products screening program. J Ind Microbiol Biotechnol 2000; 25: 315-27.
109. Iwasaki S, Omura S. Search for protein farnesyltransferase inhibitors of microbial origin: our strategy and results as well as the results obtained by other groups. J Antibiot (Tokyo) 2007; 60: 1-12.
110. Laezza C, Fiorentino L, Pisanti S, et al. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J Mol Med (Berl) 2008; 86: 1341-51.
111. Nagase T, Kawata S, Tamura S, et al. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells. Br J Cancer 1997; 76: 1001-10.
112. Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res 2005; 65: 2993-5.
113. Tardy C, Codogno P, Autefage H, Levade T, Andrieu-Abadie N. Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle). Biochim Biophys Acta 2006; 1765: 101-25.
114. Mathiasen IS, Hansen CM, Foghsgaard L, Jaattela M. Sensitization to TNF-induced apoptosis by 1, 25-dihydroxy vitamin D3 involves up-regulation of the TNF receptor 1 and cathepsin B. Int J Cancer 2001; 93: 224-31.
115. Queiroz AFS, Silva RA, Moura RM, et al. Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells Cancer Chemother Pharmacol 2009; 63: 1023-33.
116. Brohem CA, Sawada TC, Massaro RR, et al. Apoptosis induction by 4-nerolidylcatechol in melanoma cell lines. Toxicol In vitro 2009; 23: 111-9.
117. Walenkamp AM, Boer IG, Bestebroer J, et al. Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration. Neoplasia 2009; 11: 333-44.
118. Walenkamp AM, Bestebroer J, Boer IG, et al. Staphylococcal SSL5 binding to human leukemia cells inhibits cell adhesion to endothelial cells and platelets. Cell Oncol 2010; 32: 1-10.
119. Bernardes N, Seruca R, Chakrabarty AM, Fialho AM. Microbialbased therapy of cancer: Current progress and future prospects. Bioeng Bugs 2010; 1: 178-90.
120. Utsugi T, Shibata J, Sugimoto Y, et al. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 1996; 56: 2809-14.
121. Subrahmanyam D, Renuka B, Rao CV, et al. Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents. Bioorg Med Chem Lett 1998; 8: 1391-6.
122. Liu YQ, Yang L, Liu Y, et al. Synthesis and insecticidal activities of novel derivatives of podophyllotoxin. Nat Prod Res 2007; 21: 967-74.
123. Greenspan EM, Leiter J, Shear MJ. Effect of α-peltatin, β-peltatin, podophyllotoxin on lymphomas and other transplanted tumors. J Natl Cancer Inst 1950; 10: 1295-333.
124. Leiter J, Downing V, Hartwell JL, Shear MJ. Damage induced in sarcoma 37 with podophyllin, podophyllotoxin α-peltatin, β-peltatin, and quercetin. J Natl Cancer Inst 1950; 10: 1273-93.
125. Stähelin HF, von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain memorial Award lecture. Cancer Res 1991; 51: 5-15.
126. Canel C, Moraes RM, Dayan FE, Ferreira D. Podophyllotoxin. Phytochemistry 2000; 54: 115-20.
127. Gordaliza M, García PA, del Corral JM, Castro MA, Gómez-Zurita MA. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004; 44: 441-59.
128. Schacter LP, Igwemezie LN, Seyedsadr M, et al. Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer Chemother Pharmacol 1994; 34(Suppl): S58-S63.
129. Budman DR. Early studies of etoposide phosphate, a water-soluble prodrug. Semin Oncol 1996; 23(Suppl 13): 8-14.
130. Greco FA, Hainsworth JD. Clinical studies with etoposide phosphate. Semin Oncol 1996; 23(Suppl 13): 45-50.
131. de Fátima A, Modolo LV, Conegero LS, et al. Styryl lactones and their derivatives: biological activities, mechanisms of action and potential leads for drug design. Curr Med Chem 2006; 13: 3371-84.
132. Ali AM, Mackeen MM, Hamid M, et al. Cytotoxicity and electron microscopy of cell death induced by goniothalamin. Planta Med 1997; 63: 81-3.
133. Pihie AH, Stanslas J, Din LB. Non-steroid receptor-mediated antiproliferative activity of styrylpyrone derivative in human breast cancer cell lines. Anticancer Res 1998; 18(3A): 1739-43.
134. Inayat-Hussain SH, Annuar BO, Din LB, Ali AM, Ross D. Loss of mitochondrial transmembrane potential and caspase-9 activation during apoptosis induced by the novel styryl-lactone goniothalamin in HL-60 leukemia cells. Toxicol In vitro 2003; 17: 433-9.
135. Chen WY, Wu CC, Lan YH, Chang FR, Teng CM, Wu YC. Goniothalamin induces cell cycle-specific apoptosis by modulating the redox status in MDA-MB-231 cells. Eur J Pharmacol 2005; 522: 20-9.
136. de Fátima A, Kohn LK, Antônio MA, de Carvalho JE, Pilli RA. (R)-Goniothalamin: total syntheses and cytotoxic activity against cancer cell lines. Bioorg Med Chem 2005; 13: 2927-33.
137. Chan KM, Rajab NF, Ishak MH, et al. Goniothalamin induces apoptosis in vascular smooth muscle cells. Chem Biol Interact 2006; 159: 129-40.
138. de Fátima A, Zambuzzi WF, Modolo LV, et al. Cytotoxicity of goniothalamin enantiomers in renal cancer cells: involvement of nitric oxide, apoptosis and autophagy. Chem Biol Interact 2008; 176: 143-50.
139. Inayat-Hussain SH, Wong LT, Chan KM, et al. RACK-1 overexpression protects against goniothalamin-induced cell death. Toxicol Lett 2009; 191: 118-22.
140. Inayat-Hussain SH, Chan KM, Rajab NF, et al. Goniothalamininduced oxidative stress, DNA damage and apoptosis via caspase-2 independent and Bcl-2 independent pathways in Jurkat T-cells. Toxicol Lett 2010; 193: 108-14.
141. Meenakshii N, Lee A, Azimahtol HLP, Hasidah S. Increased levels of apoptosis correlate with p53 protein accumulation in response to the styrylpyrone derivative (SPD) treatment of the "Huggins Tumour". Malaysian Appl Biol 2000; 29: 121-6.
142. Vendramini-Costa DB, de Castro IB, Ruiz AL, Marquissolo C, Pilli RA, de Carvalho JE. Effect of goniothalamin on the development of Ehrlich solid tumor in mice. Bioorg Med Chem 2010; 18: 6742-7.
143. Fátima A, Kohn LK, Carvalho JE, Pilli RA. Cytotoxic activity of (S)-goniothalamin and analogues against human cancer cells. Bioorg Med Chem 2006; 14: 622-31.
144. Kasaplar P, Yilmazer O, Caǧir A. 6-Bicycloaryl substituted (S)-and (R)-5,6-dihydro-2H-pyran-2-ones: asymmetric synthesis, and anti-proliferative properties. Bioorg Med Chem 2009; 17: 311-8.
145. Bialy L, Waldmann H. Synthesis and biological evaluation of cytostatin analogues. Chem Commun (Camb) 2003; 15: 1872-3.
146. Buck SB, Hardouin C, Ichikawa S, et al. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. J Am Chem Soc 2003; 125: 15694-5.
147. Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 2007; 102: 580-592.